Tag Archives: diabetic macular edema

Boehringer Ingelheim partners with Palatin Technologies to develop novel melanocortin-based therapy for diabetic retinopathy and retinal diseases

(IN BRIEF) Boehringer Ingelheim has entered into a global collaboration and licensing agreement with Palatin Technologies to develop melanocortin receptor agonists as a new treatment for retinal diseases, beginning with diabetic retinopathy and diabetic macular edema. The approach targets inflammation, … Read the full press release

Boehringer Ingelheim Launches Phase II Trial of Oral BI 1815368 to Treat Diabetic Macular Edema

(IN BRIEF) Boehringer Ingelheim has initiated the THULITE Phase II trial (NCT06962839) to assess BI 1815368, a novel oral agent for diabetic macular edema (DME). Affecting more than 21 million people globally, DME is typically managed by frequent eye injections, … Read the full press release

Roche to present new two-year data for its Vabysmo and Susvimo at Angiogenesis, Exudation and Degeneration 2022 on 12 February

In the YOSEMITE and RHINE studies in diabetic macular edema, at least 60% of eligible Vabysmo patients could extend treatment to every four months at two years, compared to 50% at year one Almost 80% of eligible Vabysmo patients could extend treatment to every … Read the full press release